

WHAT IS ABRYSVO?

ABRYSVO is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

IMPORTANT SAFETY INFORMATION


 ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components

Please see Important Safety Information continued on pages 2–6. Please click for full Prescribing Information for Abrysvo.

Pfizer's ABRYSVO® (Respiratory Syncytial Virus Vaccine) is the only maternal vaccine that helps protect your infant from first breath through 6 months.

For more information, or to find Pfizer's ABRYSVO at a pharmacy or OB-GYN near you, visit

www.abrysvo.com






Use your smartphone camera to scan to find where to get **ABRYSVO** near you.

IMPORTANT SAFETY INFORMATION (continued)

 To avoid the potential risk of preterm birth, ABRYSVO should be given during 32 through 36 weeks gestational age

Please see Important Safety Information continued on pages 1–6. Please click for full <u>Prescribing Information</u> for Abrysvo.

RSV is a highly contagious respiratory virus that can potentially make your baby sick, especially if they're under 6 months old.



Respiratory syncytial virus (RSV) is a virus that affects the lungs and airways, and spreads easily. Like the flu, it can go from mild to severe, where your baby may struggle to take a breath.

RSV may cause a baby to develop symptoms like:

- Difficulty breathing
- Wet cough

- Pneumonia
- Wheezing

IMPORTANT SAFETY INFORMATION (continued)

- Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury due to fainting
- Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO®

Please see Important Safety Information on pages 1-6.

Learn about RSV and the risk to your baby.



Nearly 50% of all RSV hospitalizations during the first year occur during the first 3 months of life.



75–80% of hospitalizations due to RSV happened during the first 6 months of life.



Vaccinating with ABRYSVO® (Respiratory Syncytial Virus Vaccine) during weeks 32 to 36 of pregnancy helps protect your baby against RSV during their first 6 months.



IMPORTANT SAFETY INFORMATION (continued)

- Vaccination with ABRYSVO may not protect all people
- In pregnant individuals, the most common side effects (≥10%) were pain at the injection site, headache, muscle pain, and nausea

Please see Important Safety Information continued on pages 1–6. Please click for full <u>Prescribing Information</u> for Abrysvo.



Help protect infants against the risk of RSV from birth to 6 months.

Pfizer's ABRYSVO® (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

ABRYSVO works by boosting your immune system, which allows your body to pass that protection to your baby before they are born. Your baby is born with your antibodies in their system, which can help protect them from RSV at birth.

The CDC recommends Abrysvo if you are 32 through 36 weeks pregnant during September through January (in most of the continental United States). However, there are areas in the U.S., including southern Florida, Alaska, Hawaii, and the U.S. territories, where RSV does not follow the typical seasonal patterns and the recommended months for maternal vaccination may differ. Talk to your OB-GYN to learn more about how to protect your baby against RSV during their first RSV season and whether Abrysvo is right for you.

IMPORTANT SAFETY INFORMATION (continued)

 In clinical trials where ABRYSVO was compared to placebo, infants born to pregnant individuals experienced low birth weight (5.1% ABRYSVO versus 4.4% placebo) and jaundice (7.2% ABRYSVO versus 6.7% placebo)

Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.

Savings and Support

Pfizer's ABRYSVO® (Respiratory Syncytial Virus Vaccine) may be available to you at no cost in accordance with the Inflation Reduction Act. Certain vaccines may be covered or available at lower out-of-pocket costs in Medicare Part D, Medicaid, the Children's Health Insurance Program, or other consumer plans through the Inflation Reduction Act. For more information, visit cms.gov.



Talk to your doctor or pharmacist to see if Pfizer's ABRYSVO is covered under your insurance plan. Additional savings and support options are available through Pfizer Vaccine Reimbursement Support Services.



IMPORTANT SAFETY INFORMATION

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).

Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see Important Safety Information continued on pages 1-6. Please click for full Prescribing Information for Abrysvo.